Instem full year hangs in the balance

Instem Life Sciences, a software provider to the healthcare industry, said several contracts needed to meet revenue and profit expectations for the year remain pending.

The group, which previously cautioned that research organisations, which make up the bulk of its client base, are being cautious in software investment, has seen its share price plunge 57% in the last 12 months.

In its update on trading for the year ending December 31st 201 Instem added that their clients' ability to contribute to current year results will only be known definitively at the year-end.

Start your trial of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

As a result, Instem now intends to announce its planned trading update in early January.

Shares of Instem fell 2.2% at 08:40 in London.

CJ